Overview

Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the non-inferiority in the efficacy of DRV/r (900/100 mg) monotherapy at 48 weeks versus LPV/r (400/100 mg) as simplification strategy in subjects with sustained viral suppression on stable PI or NNRTI-antiretroviral regimens.

Phase:

Phase 4

Details

Lead Sponsor:

Germans Trias i Pujol Hospital

Treatments:

Darunavir
Lopinavir
Ritonavir